Dr. Yuling Luo received a B.S. in Chemistry from the University of Science & Technology of China and earned a Ph.D. in Biochemistry from Case Western Reserve University. He has spent his entire career building life science startup companies as an innovator and serial entrepreneur. Dr. Luo is currently the Founder, Chairman and CEO of Alamar Biosciences, where he is the lead inventor of the NULISA™ technology and spearheads the company’s reinvention of immunoassays to enable ultra-sensitive and highly multiplexed protein liquid biopsy analysis for early detection of disease. Prior to Alamar, Dr. Luo was the visionary and inventor of RNAscope®, a breakthrough molecular detection technology that has pioneered spatial biology and become the gold standard in RNA tissue imaging. As the Founder, President and CEO of Advanced Cell Diagnostics (ACD), he led the company from concept to successful product launch and commercialization. Under his leadership, ACD became one of the fastest growing life sciences companies, and was acquired by Bio-Techne in 2016. Before ACD, Dr. Luo was a co-founder of Panomics (formerly Genospectra), a life science company that was acquired by Affymetrix in 2008. Prior to Panomics, he was one of the earliest senior scientists at Exelixis, now a NASDAQ company. He also co-founded and served as chairman of the board of Avida Biomed, which was acquired by Agilent in 2022. Dr. Luo is also a co-founder and board member of Attovia Therapeutics and a Venture Partner of Illumina Ventures. Dr. Luo has published numerous research papers in top peer-reviewed journals and his inventions are the subject of over 30 issued patents.